RxDoctor Payments DataLook up a doctor →

Randle Middleton, MD

Family Medicine · Huntsville, ALNPI 1801845920

Payments from drug & device makers

$3,307,725in general payments, 2019–2025

Across 870 payments — averaging $3801.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$746K
  • Sanofi Pasteur Inc.$598K
  • Janssen Research & Development, LLC$547K
  • Modernatx, Inc.$385K
  • Takeda Pharmaceuticals U.S.A., Inc.$380K
  • Valneva Austria GmbH$265K
  • plus $386K from 48 others
$1,748in research payments, 2019–2025

Across 13 payments — averaging $134.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi Pasteur Inc.$2K

What the payments were for

  • Food & beverage$5,293100%
  • Gifts$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer97$745,959
Sanofi Pasteur Inc.72$598,159
Janssen Research & Development, LLC28$547,130
Modernatx, Inc.148$384,547
Takeda Pharmaceuticals U.S.A., Inc.16$380,426
Valneva Austria GmbH2$265,244
Emergent Biosolutions Inc.12$232,301
Seqirus USA Inc134$118,011
AstraZeneca15$16,115
Dynavax Technologies Corporation48$10,180
Novartis15$3,733
Bavarian Nordic A/s2$1,300
AbbVie(2 entities)45$592
Lilly USA, LLC37$550
GSK25$417
Amgen21$404
Novo Nordisk27$378
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$321
Biohaven Pharmaceuticals, Inc.11$278
Biohaven Pharmaceutical Holding Company Ltd.10$227
Sumitomo Pharma America, Inc.6$116
Bayer5$115
Astellas Pharma US Inc5$100
Otsuka America Pharmaceutical, Inc.5$98
Aytu Biopharma, Inc.5$90
Phathom Pharmaceuticals, Inc.7$79
Johnson & Johnson5$71
Merck4$68
Kowa Pharmaceuticals America, Inc.4$61
Teva Pharmaceuticals USA, Inc.4$55
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$54
Boehringer Ingelheim4$53
Axsome Therapeutics, Inc.2$51
IBSA Pharma Inc.3$50
Genentech USA, Inc.3$48
Biogen2$42
Regeneron Healthcare Solutions, Inc.2$29
Idorsia Pharmaceuticals US Inc1$25
Paratek Pharmaceuticals, Inc.1$25
Pharming Healthcare, Inc.1$23
Bioventus LLC1$22
E.r. Squibb & Sons, L.L.C.1$18
Lundbeck LLC1$18
Antares Pharma, Inc.1$18
Esperion Therapeutics, Inc.1$15
Assertio Therapeutics, Inc.1$14
Supernus Pharmaceuticals, Inc.1$14
Arbor Pharmaceuticals, Inc.1$13
Corium, LLC1$12
Bausch Health US, LLC1$12
Zyla Life Sciences, Inc.1$12
Ironwood Pharmaceuticals, Inc1$12
Shire North American Group Inc1$11
Amarin Pharma, Inc.1$11

How this compares

$3,307,725 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$135,617
Medicare patients
195
Services billed
1,870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide25$31,170
JardianceEmpagliflozin28$27,211
FarxigaDapagliflozin Propanediol32$22,411
EliquisApixaban18$14,407
TrulicityDulaglutide12$11,048
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,056
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,697
MyrbetriqMirabegron15$6,394
XareltoRivaroxaban12$6,357
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$6,069
Novolog FlexpenInsulin Aspart16$5,889
TrintellixVortioxetine Hydrobromide12$5,632
PremarinEstrogens, Conjugated11$4,083
SynthroidLevothyroxine Sodium32$3,536
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro$550$42,84850 claims
AstraZenecaFarxiga, Breztri Aerosphere$16,115$29,10943 claims
Boehringer IngelheimJardiance$53$27,21128 claims
PfizerEliquis, Premarin$745,959$18,49029 claims
GSKTrelegy Ellipta$417$7,05612 claims
Astellas Pharma US IncMyrbetriq$100$6,39415 claims
Johnson & JohnsonXarelto$71$6,35712 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$380,426$5,63212 claims
AbbVieSynthroid$592$3,53632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →